Description

RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neurodegeneration–C59H102F3N13O19S—Int J Biol Sci. 2024 Jan 1;20(2):784-800.|Cell Commun Signal. 2023 May 1;21(1):86.-[1]Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64.|[2]Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13.—-1386.58–99.71–O=C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)NC(C)=O.O=C(O)C(F)(F)F–Cancer; Inflammation/Immunology–DMSO : ≥ 50 mg/mL|H2O : 14.29 mg/mL (ultrasonic)–Amyloid-β—-Neuronal Signaling–Peptides